StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
103
This year
3
Publishing Date
2023 - 06 - 28
2
2023 - 05 - 31
3
2023 - 05 - 30
2
2023 - 05 - 29
4
2023 - 05 - 26
3
2022 - 11 - 08
2
2022 - 11 - 02
1
2022 - 10 - 31
1
2022 - 09 - 28
1
2022 - 09 - 06
1
2022 - 08 - 22
1
2022 - 08 - 09
1
2022 - 08 - 08
1
2022 - 08 - 01
1
2022 - 07 - 11
1
2022 - 06 - 23
1
2022 - 06 - 08
1
2022 - 05 - 26
1
2022 - 05 - 18
1
2022 - 05 - 10
1
2022 - 04 - 28
1
2022 - 04 - 06
1
2022 - 04 - 05
1
2022 - 03 - 31
1
2022 - 02 - 28
1
2022 - 02 - 18
2
2022 - 02 - 16
1
2022 - 02 - 04
1
2022 - 01 - 31
1
2022 - 01 - 30
2
2022 - 01 - 21
1
2022 - 01 - 14
1
2021 - 12 - 31
1
2021 - 12 - 08
1
2021 - 12 - 02
2
2021 - 11 - 08
1
2021 - 11 - 01
1
2021 - 10 - 28
1
2021 - 10 - 06
1
2021 - 09 - 30
2
2021 - 08 - 09
1
2021 - 08 - 02
1
2021 - 07 - 12
1
2021 - 06 - 29
1
2021 - 06 - 07
1
2021 - 05 - 19
2
2021 - 05 - 14
1
2021 - 05 - 11
1
2021 - 05 - 06
1
2021 - 05 - 03
2
2021 - 04 - 28
1
2021 - 04 - 27
1
2021 - 04 - 26
1
2021 - 04 - 15
1
2021 - 03 - 15
1
2021 - 03 - 01
2
2021 - 02 - 22
1
2020 - 12 - 04
2
2020 - 12 - 02
1
2020 - 12 - 01
1
Sector
Commercial services
1
Finance
6
Health technology
103
Industrial services
1
Producer manufacturing
1
Technology services
1
Tags
100
3
Acquire
1
Acquisition
2
Acquisition corp
1
Als
9
Application
4
Approval
9
Berubicin
24
Biopharma
1
Biotech-bay
1
Ces
5
Change
1
Commercial
1
Companies
2
Company announcement
3
Conference
7
Covid-19
1
Deadline
7
Designation
5
Disease
4
Drug
5
Earnings
6
Europe
2
Events
3
Fast track
3
Fast track designation
2
Fda
12
Fda-approvals
2
Financial
4
Financial results
9
Friedreich's ataxia
2
Friedreich’s ataxia
6
Glioblastoma
13
Global
6
Growth
2
Kidney
4
Lone-star-bio
26
Market
2
N/a
48
Offering
4
Ongoing
10
People
3
Pharmaceuticals
21
Potential
14
Presentation
5
Program
3
Regulatory
3
Report
3
Research
5
Results
17
Review
2
Skyclarys
2
Study
7
Submission
3
Switzerland
3
Syndros
4
Therapeutics
2
Treatment
28
Trial
11
Update
6
Entities
Abbott laboratories
2
Abbvie inc.
1
Aldeyra therapeutics, inc.
1
Alnylam pharmaceuticals, inc.
1
Amgen inc.
1
Apollo endosurgery, inc.
1
Astrazeneca plc
1
Biogen inc.
3
Catalent, inc.
1
Chinook therapeutics, inc.
1
Cns pharmaceuticals, inc.
29
Docusign, inc.
1
Eli lilly and company
2
Franchise group, inc.
1
Ies holdings, inc.
1
Karyopharm therapeutics inc.
2
Kiniksa pharmaceuticals, ltd.
1
Kornit digital ltd.
1
Moleculin biotech, inc.
2
Novartis ag
1
Novo nordisk a/s
2
Pfizer, inc.
1
Phathom pharmaceuticals, inc.
7
Pulse biosciences, inc
1
Rallybio corp
1
Reata pharmaceuticals, inc.
103
Replimune group, inc.
1
Sanofi
4
Sarepta therapeutics, inc.
1
Sierra oncology, inc.
1
Stoke therapeutics, inc.
1
Summit therapeutics inc.
1
Texas capital bancshares, inc.
6
Verona pharma plc
1
Xencor, inc.
1
Symbols
AAPL
1198
ABB
1433
ABBV
1030
ABLZF
1172
ABT
1797
ACN
602
AMGN
744
ARVL
4321
AVGO
597
AZN
668
BDX
796
BMY
662
BNPQF
1769
BNPQY
1769
CSCO
900
DHR
786
ERIC
1617
F
643
FNCTF
7229
FRBA
602
GE
919
GLAXF
661
GOOG
1297
GOOGL
1296
GSK
887
HON
1793
HUBS
1400
IBM
657
INTC
955
IT
595
JNJ
4608
LLY
1712
LTUM
973
LYV
717
MDT
1286
MMM
938
MS
4299
MSFT
1205
MT
593
NOK
917
NOKBF
993
NVO
636
NVS
1245
NVSEF
1035
ORCL
1161
PCRFF
651
PCRFY
651
PFE
693
PHG
963
PPRUF
1132
PPRUY
1133
SAP
1481
SAPGF
1235
SNOW
796
SNY
4562
SNYNF
3620
TEVJF
633
TMO
1630
VZ
1223
XYF
678
Exchanges
Nasdaq
103
Nyse
6
Crawled Date
2023 - 06 - 28
2
2023 - 05 - 31
3
2023 - 05 - 30
2
2023 - 05 - 29
4
2023 - 05 - 26
3
2022 - 11 - 08
2
2022 - 11 - 02
1
2022 - 11 - 01
1
2022 - 09 - 28
1
2022 - 09 - 06
1
2022 - 08 - 22
1
2022 - 08 - 09
1
2022 - 08 - 08
1
2022 - 08 - 01
1
2022 - 07 - 11
1
2022 - 06 - 23
1
2022 - 06 - 08
1
2022 - 05 - 26
1
2022 - 05 - 18
1
2022 - 05 - 10
1
2022 - 04 - 28
1
2022 - 04 - 06
1
2022 - 04 - 05
1
2022 - 03 - 31
1
2022 - 02 - 28
1
2022 - 02 - 18
2
2022 - 02 - 16
1
2022 - 02 - 04
1
2022 - 01 - 31
1
2022 - 01 - 30
2
2022 - 01 - 21
1
2022 - 01 - 14
1
2021 - 12 - 31
1
2021 - 12 - 08
1
2021 - 12 - 02
2
2021 - 11 - 08
1
2021 - 11 - 01
1
2021 - 10 - 28
1
2021 - 10 - 06
1
2021 - 09 - 30
2
2021 - 08 - 09
1
2021 - 08 - 02
1
2021 - 07 - 12
1
2021 - 06 - 29
1
2021 - 06 - 07
1
2021 - 05 - 19
2
2021 - 05 - 14
1
2021 - 05 - 11
1
2021 - 05 - 06
1
2021 - 05 - 03
2
2021 - 04 - 28
1
2021 - 04 - 27
1
2021 - 04 - 26
1
2021 - 04 - 15
1
2021 - 03 - 15
1
2021 - 03 - 01
2
2021 - 02 - 22
1
2020 - 12 - 04
2
2020 - 12 - 02
1
2020 - 12 - 01
1
Crawled Time
00:00
3
02:00
4
03:00
2
04:00
1
05:00
2
08:00
1
08:20
1
09:00
9
10:00
2
11:00
8
12:00
13
12:15
2
12:20
2
12:30
2
13:00
10
13:15
1
13:20
2
13:30
1
14:00
6
14:20
2
14:30
1
15:00
5
15:30
1
16:00
3
17:00
2
18:00
3
19:00
2
20:00
2
20:20
2
21:00
3
21:05
1
22:00
3
23:00
1
Source
apolloendo.com
1
www.biospace.com
52
www.globenewswire.com
17
www.prnewswire.com
33
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
symbols :
RETA
save search
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published:
2024-01-17
(Crawled : 14:30)
- biospace.com/
CNSP
|
News
|
$0.2002
-4.67%
-4.9%
76K
|
Health Technology
|
-70.85%
|
O:
5.82%
H:
7.57%
C:
-7.32%
berubicin
treatment
pharmaceuticals
glioblastoma
study
Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics
Published:
2024-01-10
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
-9.7%
|
O:
1.1%
H:
0.0%
C:
0.0%
NVO
|
News
|
$126.16
-1.93%
-0.23%
3.1M
|
Health Technology
|
16.09%
|
O:
-0.33%
H:
0.35%
C:
-1.5%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
19.36%
|
O:
0.67%
H:
0.85%
C:
0.21%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-8.72%
|
O:
0.69%
H:
0.0%
C:
0.0%
ALDX
|
$3.93
0.51%
0.51%
570K
|
Health Technology
|
17.96%
|
O:
-1.8%
H:
0.46%
C:
-2.44%
companies
therapeutics
growth
market
Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock
Published:
2024-01-08
(Crawled : 13:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
Email alert
Add to watchlist
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Published:
2023-11-22
(Crawled : 15:00)
- biospace.com/
CNSP
|
News
|
$0.2002
-4.67%
-4.9%
76K
|
Health Technology
|
-89.95%
|
O:
3.35%
H:
25.0%
C:
4.17%
berubicin
ongoing
pharmaceuticals
study
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Published:
2023-11-07
(Crawled : 15:00)
- biospace.com/
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
|
18.34%
|
O:
-0.28%
H:
0.0%
C:
0.0%
SMMT
|
$3.605
-3.35%
-3.47%
1.3M
|
Health Technology
|
64.68%
|
O:
-0.46%
H:
6.68%
C:
-11.75%
PLSE
|
$6.86
0.0%
130K
|
Health Technology
|
32.18%
|
O:
0.39%
H:
6.43%
C:
1.92%
BIIB
|
$201.91
4.52%
4.32%
3.3M
|
Health Technology
|
-18.76%
|
O:
-0.82%
H:
0.73%
C:
-0.4%
ALNY
|
$143.8
-1.55%
-1.58%
390K
|
Health Technology
|
-13.97%
|
O:
1.06%
H:
2.42%
C:
0.76%
therapeutics
financial
results
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Published:
2023-10-11
(Crawled : 13:00)
- biospace.com/
CNSP
|
News
|
$0.2002
-4.67%
-4.9%
76K
|
Health Technology
|
-80.37%
|
O:
-2.8%
H:
18.26%
C:
13.46%
rapid
berubicin
treatment
ongoing
glioblastoma
study
Biogen Completes Acquisition of Reata Pharmaceuticals
Published:
2023-09-26
(Crawled : 13:00)
- globenewswire.com
BIIB
|
$201.91
4.52%
4.32%
3.3M
|
Health Technology
|
-20.79%
|
O:
-0.02%
H:
1.37%
C:
1.21%
acquisition
pharmaceuticals
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Published:
2023-08-14
(Crawled : 13:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
2.91%
|
O:
0.31%
H:
1.04%
C:
0.76%
CNSP
|
News
|
$0.2002
-4.67%
-4.9%
76K
|
Health Technology
|
-89.66%
|
O:
-2.46%
H:
2.53%
C:
-10.61%
berubicin
pharmaceuticals
therapy
results
study
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published:
2023-08-03
(Crawled : 12:20)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
3.77%
|
O:
0.07%
H:
0.83%
C:
0.57%
CNSP
|
News
|
$0.2002
-4.67%
-4.9%
76K
|
Health Technology
|
-90.19%
|
O:
0.93%
H:
3.24%
C:
1.39%
berubicin
update
treatment
ongoing
pharmaceuticals
trial
glioblastoma
study
Biogen to Acquire Reata Pharmaceuticals
Published:
2023-07-28
(Crawled : 11:00)
- globenewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
58.78%
|
O:
51.72%
H:
1.55%
C:
1.52%
BIIB
|
$201.91
4.52%
4.32%
3.3M
|
Health Technology
|
-23.14%
|
O:
0.19%
H:
1.88%
C:
0.73%
pharmaceuticals
acquire
Chronic Kidney Disease - Market Insight, Epidemiology and Market Forecast 2023-2032: With Focus on United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan
Published:
2023-06-28
(Crawled : 02:00)
- prnewswire.com
NVO
|
News
|
$126.16
-1.93%
-0.23%
3.1M
|
Health Technology
|
-19.12%
|
O:
1.47%
H:
0.0%
C:
-0.94%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
61.94%
|
O:
0.86%
H:
0.0%
C:
-2.09%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
-11.43%
|
O:
0.75%
H:
0.0%
C:
0.0%
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
86.56%
|
O:
6.1%
H:
5.34%
C:
0.82%
disease
japan
kidney
market
Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia
Published:
2023-06-28
(Crawled : 08:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
86.56%
|
O:
6.1%
H:
5.34%
C:
0.82%
skyclarys
approval
pharmaceuticals
commercial
Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement
Published:
2023-06-16
(Crawled : 10:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
84.13%
|
O:
3.5%
H:
0.81%
C:
-3.62%
skyclarys
fda
approval
pharmaceuticals
Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer
Published:
2023-06-13
(Crawled : 12:00)
- biospace.com/
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
73.89%
|
O:
-0.83%
H:
7.38%
C:
6.11%
pharmaceuticals
research
RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
Published:
2023-06-09
(Crawled : 10:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
83.17%
|
O:
-0.15%
H:
0.96%
C:
-0.17%
potential
PHAT ALERT: The Law Offices of Vincent Wong Investigate Phathom Pharmaceuticals, Inc. for Potential Violations of Securities Laws
Published:
2023-05-31
(Crawled : 09:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
92.15%
|
O:
0.02%
H:
1.4%
C:
0.37%
PHAT
|
$9.12
0.66%
0.66%
440K
|
Health Technology
|
-20.0%
|
O:
0.88%
H:
4.78%
C:
2.26%
potential
TCBI ALERT: The Law Offices of Vincent Wong Investigate Texas Capital Bancshares, Inc. for Potential Violations of Securities Laws
Published:
2023-05-31
(Crawled : 09:00)
- prnewswire.com
TCBI
|
News
|
$60.1
-0.1%
-0.1%
300K
|
Finance
|
22.27%
|
O:
-0.31%
H:
0.33%
C:
-3.51%
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
92.15%
|
O:
0.02%
H:
1.4%
C:
0.37%
PHAT
|
$9.12
0.66%
0.66%
440K
|
Health Technology
|
-20.0%
|
O:
0.88%
H:
4.78%
C:
2.26%
potential
RETA ALERT: The Law Offices of Vincent Wong Investigate Reata Pharmaceuticals, Inc. for Potential Violations of Securities Laws
Published:
2023-05-31
(Crawled : 09:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
92.15%
|
O:
0.02%
H:
1.4%
C:
0.37%
PHAT
|
$9.12
0.66%
0.66%
440K
|
Health Technology
|
-20.0%
|
O:
0.88%
H:
4.78%
C:
2.26%
potential
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
Published:
2023-05-30
(Crawled : 09:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
86.72%
|
O:
-0.34%
H:
0.55%
C:
-2.5%
PHAT
|
$9.12
0.66%
0.66%
440K
|
Health Technology
|
-22.45%
|
O:
0.26%
H:
2.71%
C:
-3.31%
potential
RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws
Published:
2023-05-30
(Crawled : 09:00)
- prnewswire.com
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
|
86.72%
|
O:
-0.34%
H:
0.55%
C:
-2.5%
PHAT
|
$9.12
0.66%
0.66%
440K
|
Health Technology
|
-22.45%
|
O:
0.26%
H:
2.71%
C:
-3.31%
potential
← Previous
1
2
3
4
5
6
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.